High Blood Pressure & Cardiovascular Prevention

, Volume 26, Issue 5, pp 421–423 | Cite as

Resveratrol for High Blood Pressure: A Total Failure or the Need to Identify the Right Patient?

  • Federica FogacciEmail author
  • Silvia Fogacci
  • Arrigo Cicero


Compliance with Ethical Standards

Conflict of interest

Arrigo F. G. Cicero has given talks, furnished scientific consultancies and/or participated in trials sponsored by Amgen, Angelini, Menarini and Mylan; Federica Fogacci has served as consultant for Mylan and Roelmi HPC; Silvia Fogacci has no conflict of interest.


  1. 1.
    Cicero AFG, Fogacci F, Banach M. Botanicals and phytochemicals active on cognitive decline: the clinical evidence. Pharmacol Res. 2018;130:204–12. Scholar
  2. 2.
    Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32(12):1377–82.CrossRefGoogle Scholar
  3. 3.
    Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci. 2011;1215:9–15. Scholar
  4. 4.
    Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493–506.CrossRefGoogle Scholar
  5. 5.
    Cicero AFG, Fogacci F, Colletti A. Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach. Food Funct. 2017;8(6):2076–88. Scholar
  6. 6.
    Akbari M, Tamtaji OR, Lankarani KB, Tabrizi R, Dadgostar E, Kolahdooz F, Jamilian M, Mirzaei H, Asemi Z. The effects of resveratrol supplementation on endothelial function and blood pressures among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. High Blood Press Cardiovasc Prev. 2019. Scholar
  7. 7.
    Fogacci F, Tocci G, Presta V, Fratter A, Borghi C, Cicero AFG. Effect of resveratrol on blood pressure: a systematic review and meta-analysis of randomized, controlled, clinical trials. Crit Rev Food Sci Nutr. 2019;59(10):1605–18. Scholar
  8. 8.
    Fogacci F, Banach M, Cicero AFG. Resveratrol effect on patients with non-alcoholic fatty liver disease: a matter of dose and treatment length. Diabetes Obes Metab. 2018;20(7):1798–9. Scholar
  9. 9.
    Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol. 2018;84(9):1906–16. Scholar
  10. 10.
    Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM, Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini T, Swan L, Warnes CA, ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165–241. Scholar
  11. 11.
    Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, Howard VJ, Lichtman JH, Lisabeth LD, Piña IL, Reeves MJ, Rexrode KM, Saposnik G, Singh V, Towfighi A, Vaccarino V, Walters MR, American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council for High Blood Pressure Research. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(5):1545–88. Scholar
  12. 12.
    ACOG Practice Bulletin No. 202. Gestational hypertension and preeclampsia. Obstet Gynecol. 2019;133(1):e1–25. Scholar
  13. 13.
    Ding J, Kang Y, Fan Y, Chen Q. Efficacy of resveratrol to supplement oral nifedipine treatment in pregnancy-induced preeclampsia. Endocr Connect. 2017;6(8):595–600. Scholar
  14. 14.
    Cudmore MJ, Ramma W, Cai M, Fujisawa T, Ahmad S, Al-Ani B, Ahmed A. Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta. Am J Obstet Gynecol. 2012;206(3):253.e10–5. Scholar
  15. 15.
    Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374(1):13–22. Scholar
  16. 16.
    Frusca T, Gervasi MT, Paolini D, Dionisi M, Ferre F, Cetin I. Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia. J Matern Fetal Neonatal Med. 2017;30(18):2166–73. Scholar
  17. 17.
    Pandey AK, Bhattacharya P, Shukla SC, Paul S, Patnaik R. Resveratrol inhibits matrix metalloproteinases to attenuate neuronal damage in cerebral ischemia: a molecular docking study exploring possible neuroprotection. Neural Regen Res. 2015;10(4):568–75. Scholar
  18. 18.
    Chen J, Bai Q, Zhao Z, Sui H, Xie X. Resveratrol improves delayed r-tPA treatment outcome by reducing MMPs. Acta Neurol Scand. 2016;134(1):54–60. Scholar
  19. 19.
    Montagnana M, Lippi G, Albiero A, Scevarolli S, Salvagno GL, Franchi M, Guidi GC. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal. 2009;23(2):88–92. Scholar
  20. 20.
    Palei AC, Granger JP, Tanus-Santos JE. Matrix metalloproteinases as drug targets in preeclampsia. Curr Drug Targets. 2013;14(3):325–34.PubMedPubMedCentralGoogle Scholar

Copyright information

© Italian Society of Hypertension 2019

Authors and Affiliations

  1. 1.Medical and Surgical Sciences Department, Sant’Orsola-Malpighi University Hospital, Dyslipidemia and Atherosclerosis Research Group, U.O. Medicina Interna BorghiUniversity of BolognaBolognaItaly
  2. 2.Italian Nutraceutical Society (SINut)BolognaItaly

Personalised recommendations